Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Cephalon, Inc. et al v. Celgene Corp. et al
Case Number:
1:11-cv-12226
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 19, 2015
Acusphere Fights Celgene's Bid For Atty Fees In Patent Row
Specialty pharmaceutical company Acusphere Inc. fought back Tuesday against Celgene Corp.'s bid for attorneys' fees in a patent dispute over anti-tumor drug Abraxane, telling a Massachusetts federal court there was nothing frivolous about its case.
-
March 18, 2014
Celgene Ducks Teva Unit's Breast-Cancer Drug IP Claims
A Massachusetts federal judge entered an order Tuesday clearing Celgene Corp. of allegations that its antitumor drug Abraxane infringed a Teva Pharmaceutical Industries Ltd. unit's patent covering the drug's active ingredient, after the parties agreed his claim construction ruling precluded an infringement finding.
-
December 15, 2011
Teva Unit Targets Celgene Breast Cancer Drug In IP Suit
Teva Pharmaceutical Industries Ltd. unit Cephalon Inc. on Wednesday hit Celgene Corp. with a lawsuit claiming Celgene's breast cancer treatment Abraxane infringes a patent covering formulations of paclitaxel, the drug's active ingredient.